Schonfeld Strategic Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4M	Buy	+127,302	New	+$3.76M	0.01%	739
2025 Q2	–	Sell	-97,529	Closed	-$2.37M	–	2111
2025 Q1	$2.37M	Buy	97,529 +24,549	+34%	+$553K	0.01%	881
2024 Q4	$1.52M	Buy	+72,980	New	+$1.57M	0.01%	945
2024 Q1	–	Sell	-16,887	Closed	-$284K	–	2118
2023 Q4	$284K	Buy	+16,887	New	+$231K	﹤0.01%	1444
2022 Q4	–	Sell	-176,506	Closed	-$2.27M	–	2654
2022 Q3	$2.27M	Buy	+176,506	New	+$2.09M	0.02%	812
2022 Q2	–	Sell	-23,288	Closed	-$193K	–	2610
2022 Q1	$193K	Buy	+23,288	New	+$165K	﹤0.01%	1995
2018 Q1	–	Sell	-38,997	Closed	-$153K	–	789
2017 Q4	$153K	Buy	+38,997	New	+$129K	0.01%	689

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Schonfeld Strategic Advisors's CPRX Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 127,302 shares worth $4M. The stake represents 0.01% of the portfolio and ranks #739 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CPRX as recently as Q1 2025.

Schonfeld Strategic Advisors first reported a position in CPRX in Q4 2017 and has held it in 7 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Schonfeld Strategic Advisors held 127,302 shares of Catalyst Pharmaceutical worth $4M as of Q2 2026.
Catalyst Pharmaceutical was a new Schonfeld Strategic Advisors position in Q2 2026.
Catalyst Pharmaceutical made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #739 holding.
Schonfeld Strategic Advisors first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 7 quarters since.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.